$65.97 Million in Sales Expected for Neurocrine Biosciences (NBIX) This Quarter

Wall Street analysts expect Neurocrine Biosciences (NASDAQ:NBIX) to post $65.97 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $71.04 million and the lowest estimate coming in at $59.20 million. The company is scheduled to report its next earnings report on Tuesday, May 8th.

On average, analysts expect that Neurocrine Biosciences will report full year sales of $373.62 million for the current year, with estimates ranging from $327.30 million to $420.00 million. For the next year, analysts forecast that the firm will post sales of $615.22 million per share, with estimates ranging from $563.84 million to $648.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that follow Neurocrine Biosciences.

How to Become a New Pot Stock Millionaire

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.18 by ($0.11). The company had revenue of $94.52 million during the quarter, compared to analysts’ expectations of $94.00 million. During the same period last year, the company earned ($0.51) earnings per share.



A number of equities research analysts recently weighed in on the company. Oppenheimer set a $110.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, April 10th. BidaskClub lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, April 4th. ValuEngine upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Piper Jaffray reiterated an “overweight” rating and issued a $113.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, March 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $110.00 price objective (up from $95.00) on shares of Neurocrine Biosciences in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $95.23.

NBIX stock traded down $2.93 during midday trading on Tuesday, reaching $78.43. 638,268 shares of the company’s stock traded hands, compared to its average volume of 881,310. Neurocrine Biosciences has a 1-year low of $41.76 and a 1-year high of $92.98. The stock has a market capitalization of $7,136.64, a price-to-earnings ratio of -48.41 and a beta of 0.29. The company has a debt-to-equity ratio of 0.99, a current ratio of 10.20 and a quick ratio of 10.20.

In other news, insider Haig P. Bozigian sold 75,873 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the transaction, the insider now directly owns 18,041 shares in the company, valued at approximately $1,623,690. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dimitri E. Grigoriadis sold 86,368 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $78.32, for a total value of $6,764,341.76. Following the completion of the transaction, the insider now owns 154,717 shares in the company, valued at $12,117,435.44. The disclosure for this sale can be found here. Insiders sold a total of 361,761 shares of company stock worth $29,576,784 over the last 90 days. 4.30% of the stock is owned by corporate insiders.

Several large investors have recently bought and sold shares of NBIX. The Manufacturers Life Insurance Company lifted its holdings in Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Neurocrine Biosciences by 233.6% during the third quarter. Russell Investments Group Ltd. now owns 27,875 shares of the company’s stock worth $1,708,000 after acquiring an additional 19,518 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Neurocrine Biosciences during the third quarter worth about $1,633,000. Legal & General Group Plc lifted its holdings in Neurocrine Biosciences by 14.6% during the third quarter. Legal & General Group Plc now owns 36,497 shares of the company’s stock worth $2,237,000 after acquiring an additional 4,638 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Neurocrine Biosciences by 3.2% during the third quarter. Dimensional Fund Advisors LP now owns 181,751 shares of the company’s stock worth $11,135,000 after acquiring an additional 5,554 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://stocknewstimes.com/2018/04/24/65-97-million-in-sales-expected-for-neurocrine-biosciences-nbix-this-quarter.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply